This is a routine scientific update with no trading catalyst. Monitor Addex's cash runway (CHF 1.6M as of Dec 2025, sufficient only through mid-2026 per prior 20-F) and any Neurosterix development milestones for potential value inflection. No change to fundamental outlook.
Price Chart
Executive Summary
Addex Therapeutics announced a preclinical publication on ADX71743, a selective mGlu7 negative allosteric modulator, demonstrating effects on sleep-wake regulation and stress-related neurochemistry in animal models. The data supports the scientific rationale for Neurosterix's mGlu7 program but represents a non-material, early-stage research update with no immediate financial or regulatory impact.
Key Facts
- Publication in International Journal of Neuropsychopharmacology on ADX71743, a preclinical mGlu7 NAM
- ADX71743 increased wakefulness and reduced REM/non-REM sleep in rats; altered stress-induced neurotransmitter changes
- ADX71743 is part of the mGlu7 program being advanced by Neurosterix, a spin-out launched with Perceptive Advisors in 2024
- Addex holds a 20% equity interest in Neurosterix; no financial terms or milestones disclosed in this filing
- Prior 20-F (May 2026) reported CHF 1.6M cash, going concern emphasis, and net loss of CHF 6.8M for FY2025
Financial Impact
No financial impact from this preclinical publication; company remains pre-revenue with going concern risk per prior filing
Risk Factors
- Going concern risk: cash runway limited to mid-2026 per prior 20-F filing
- Dilution risk: active F-3 shelf registration (333-291644) incorporated by reference
- Preclinical data does not guarantee clinical success or regulatory advancement for Neurosterix's mGlu7 program
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-004524 |
| Exhibit: exh_991.htm | 0001171843-26-004524 |
| Document: 0001171843-26-004524-index-headers.html | 0001171843-26-004524 |
| Document: 0001171843-26-004524-index.html | 0001171843-26-004524 |
| Document: 0001171843-26-004524.txt | 0001171843-26-004524 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 6-K | $3.18 | awaiting T+60 | — | $2.90 (−8.81%) |
Oct 2, 2026 24d ago | 6-K | $3.07 | awaiting T+60 | — | $2.90 (−5.54%) |
Sep 28, 2026 28d ago | 6-K | $2.81 | awaiting T+60 | — | $2.90 (−3.20%) |
Sep 25, 2026 4w ago | 6-K | $3.65 | awaiting T+60 | — | $2.90 (−20.55%) |
Aug 26, 2026 8w ago | 6-K | $4.23 | awaiting T+60 | — | $2.90 (+31.44%) |
Jul 8, 2026 15w ago | 6-K | $5.89 $2.98 | ▼ −49.41% | ▼ −51.90% | $2.90 (−50.76%) |
Jun 30, 2026 16w ago | 6-K | $5.70 $3.45 | ▲ +39.47% | ▲ +42.29% | $2.90 (+49.12%) |
Jun 25, 2026 17w ago | 6-K | $5.94 $3.40 | ▲ +42.76% | ▲ +46.49% | $2.90 (+51.18%) |
May 15, 2026 23w ago | 20-F | $6.83 $5.95 | ▲ +12.88% | ▲ +17.74% | $2.90 (+57.54%) |
Apr 23, 2026 26w ago | 6-K | $6.14 $5.60 | ▼ −8.79% | ▼ −13.81% | $2.90 (−52.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers